KR20200126005A - 말초 신경의 IgG 자극된 재수초화 - Google Patents

말초 신경의 IgG 자극된 재수초화 Download PDF

Info

Publication number
KR20200126005A
KR20200126005A KR1020207030277A KR20207030277A KR20200126005A KR 20200126005 A KR20200126005 A KR 20200126005A KR 1020207030277 A KR1020207030277 A KR 1020207030277A KR 20207030277 A KR20207030277 A KR 20207030277A KR 20200126005 A KR20200126005 A KR 20200126005A
Authority
KR
South Korea
Prior art keywords
ivig
polyclonal igg
nerve
igg
neuropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207030277A
Other languages
English (en)
Korean (ko)
Inventor
패트릭 쿠에리
네베나 체코바
한스-페터 아르퉁
코리나 헤르만
비르기트 마리아 라이페르트
한스-페터 슈바르츠
하르트무트 에를리히
세바스티안 벙크
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Priority to KR1020227011045A priority Critical patent/KR102673154B1/ko
Publication of KR20200126005A publication Critical patent/KR20200126005A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
KR1020207030277A 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화 Ceased KR20200126005A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227011045A KR102673154B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
US61/605,117 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147027130A Division KR102170615B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011045A Division KR102673154B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Publications (1)

Publication Number Publication Date
KR20200126005A true KR20200126005A (ko) 2020-11-05

Family

ID=47884569

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207030277A Ceased KR20200126005A (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020227011045A Active KR102673154B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020147027130A Active KR102170615B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227011045A Active KR102673154B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020147027130A Active KR102170615B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Country Status (21)

Country Link
US (5) US8986670B2 (enExample)
EP (2) EP2820042B1 (enExample)
JP (3) JP6335800B2 (enExample)
KR (3) KR20200126005A (enExample)
CN (4) CN107551269A (enExample)
AR (2) AR090211A1 (enExample)
AU (3) AU2013203088B2 (enExample)
BR (1) BR112014021240A2 (enExample)
DK (2) DK2820042T3 (enExample)
EA (2) EA032000B1 (enExample)
ES (2) ES2755056T3 (enExample)
FI (1) FI3590960T3 (enExample)
HK (1) HK1248534A1 (enExample)
IL (3) IL277103B2 (enExample)
MX (2) MX369444B (enExample)
NZ (1) NZ629867A (enExample)
PL (2) PL3590960T3 (enExample)
PT (2) PT3590960T (enExample)
SG (1) SG11201405302WA (enExample)
TW (3) TW201838654A (enExample)
WO (1) WO2013130826A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
US20220111012A1 (en) * 2019-01-07 2022-04-14 Mallinckrodt Ard Ip Unlimited Company Methods of promoting remyelination
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3473407D1 (en) 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
WO1992003536A1 (en) * 1990-08-15 1992-03-05 University Of Miami And Its School Of Medicine Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
JP3133338B2 (ja) 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
EP2287191B1 (en) * 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
MXPA06008435A (es) * 2004-01-30 2007-05-23 Suomen Punainen Risti Veripalvelu Proceso de manufactura de una inmunoglobulina libre de virus.
ES2407380T5 (es) 2004-02-27 2017-07-07 Octapharma Ag Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus
NZ578816A (en) * 2007-02-02 2012-06-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver

Also Published As

Publication number Publication date
MX2019012496A (es) 2020-01-20
AU2016201137A1 (en) 2016-03-10
US10494418B2 (en) 2019-12-03
TW201400502A (zh) 2014-01-01
HK1206035A1 (en) 2015-12-31
PL2820042T3 (pl) 2020-03-31
EP2820042A2 (en) 2015-01-07
NZ629867A (en) 2016-09-30
EA201892521A1 (ru) 2019-07-31
AU2016201137B2 (en) 2017-10-12
IL234303B (en) 2020-09-30
IL277103A (en) 2020-10-29
DK3590960T3 (da) 2023-04-24
WO2013130826A2 (en) 2013-09-06
TWI700297B (zh) 2020-08-01
JP2020059705A (ja) 2020-04-16
CN109966488A (zh) 2019-07-05
CN104302666A (zh) 2015-01-21
SG11201405302WA (en) 2014-09-26
PL3590960T3 (pl) 2023-07-17
IL277103B1 (en) 2025-03-01
CN110343171A (zh) 2019-10-18
US20180291087A1 (en) 2018-10-11
ES2943585T3 (es) 2023-06-14
PT3590960T (pt) 2023-04-18
AU2018200026A1 (en) 2018-01-25
AR117207A2 (es) 2021-07-21
PT2820042T (pt) 2019-10-31
MX369444B (es) 2019-11-08
AU2013203088B2 (en) 2015-12-03
TWI632158B (zh) 2018-08-11
JP2015508824A (ja) 2015-03-23
EP3590960A1 (en) 2020-01-08
EA032000B1 (ru) 2019-03-29
FI3590960T3 (fi) 2023-04-25
DK2820042T3 (da) 2019-10-28
WO2013130826A3 (en) 2013-12-05
US8986670B2 (en) 2015-03-24
EA201400966A1 (ru) 2014-12-30
AR090211A1 (es) 2014-10-29
AU2018200026B2 (en) 2019-12-05
CN107551269A (zh) 2018-01-09
KR102673154B1 (ko) 2024-06-05
TW201736398A (zh) 2017-10-16
AU2013203088A1 (en) 2013-09-19
IL274512A (en) 2020-06-30
US9834593B2 (en) 2017-12-05
ES2755056T3 (es) 2020-04-21
IL277103B2 (en) 2025-07-01
EP2820042B1 (en) 2019-07-24
KR102170615B1 (ko) 2020-10-28
HK1248534A1 (zh) 2018-10-19
US20200216518A1 (en) 2020-07-09
KR20140134690A (ko) 2014-11-24
US20150232536A1 (en) 2015-08-20
US20130224150A1 (en) 2013-08-29
IL274512B2 (en) 2024-07-01
KR20220045087A (ko) 2022-04-12
TW201838654A (zh) 2018-11-01
EP3590960B1 (en) 2023-03-29
MX2014010387A (es) 2015-09-25
US20210300997A1 (en) 2021-09-30
IL274512B1 (en) 2024-03-01
JP6335800B2 (ja) 2018-05-30
BR112014021240A2 (pt) 2018-09-18
JP6979990B2 (ja) 2021-12-15
JP2018030856A (ja) 2018-03-01
JP6637934B2 (ja) 2020-01-29

Similar Documents

Publication Publication Date Title
US20210300997A1 (en) IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
US9775899B2 (en) Treating neurological disorders
Liu et al. Inorganic nitrate attenuates neuroinflammation after traumatic brain injury via Sialin
HK40018190B (en) Igg stimulated remyelination of peripheral nerves
HK40018190A (en) Igg stimulated remyelination of peripheral nerves
HK1206035B (en) Igg stimulated remyelination of peripheral nerves
Park et al. Intracortical injection of immune checkpoint inhibitor promotes monocyte/macrophage infiltration and restores microglial function and neuronal activity in an AD mouse model
EA040995B1 (ru) Ремиелинизация периферических нервов, стимулированная igg

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101000756; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20220401

Effective date: 20221027

PJ1301 Trial decision

Decision date: 20221027

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2020 7030277

Appeal request date: 20220401

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2022101000756

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

PJ1201 Withdrawal of trial

St.27 status event code: A-3-3-V10-V13-apl-PJ1201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000